Innoviva Inc
NASDAQ:INVA

Watchlist Manager
Innoviva Inc Logo
Innoviva Inc
NASDAQ:INVA
Watchlist
Price: 17.77 USD -0.11%
Market Cap: 1.1B USD
Have any thoughts about
Innoviva Inc?
Write Note

Relative Value

The Relative Value of one INVA stock under the Base Case scenario is 19.44 USD. Compared to the current market price of 17.77 USD, Innoviva Inc is Undervalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INVA Relative Value
Base Case
19.44 USD
Undervaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
26
vs Industry
34
Median 3Y
3
Median 5Y
3.2
Industry
2.5
Forward
3.1
vs History
0
vs Industry
40
Median 3Y
5.4
Median 5Y
5.3
Industry
21.8
Forward
41
vs History
4
vs Industry
41
Median 3Y
6.3
Median 5Y
4.6
Industry
16.1
vs History
14
vs Industry
31
Median 3Y
3.7
Median 5Y
4.1
Industry
23.8
vs History
55
vs Industry
47
Median 3Y
1.6
Median 5Y
2.1
Industry
2.1
vs History
65
vs Industry
27
Median 3Y
3.7
Median 5Y
3.8
Industry
2.7
Forward
3.1
vs History
33
vs Industry
40
Median 3Y
4.3
Median 5Y
0
Industry
5.2
vs History
25
vs Industry
35
Median 3Y
5.9
Median 5Y
4.6
Industry
13.5
Forward
5.1
vs History
23
vs Industry
34
Median 3Y
6.9
Median 5Y
4.8
Industry
16.8
Forward
6.5
vs History
28
vs Industry
38
Median 3Y
7.4
Median 5Y
5
Industry
15.2
vs History
28
vs Industry
30
Median 3Y
7.4
Median 5Y
5
Industry
19.3
vs History
58
vs Industry
51
Median 3Y
1.2
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

INVA Competitors Multiples
Innoviva Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Innoviva Inc
NASDAQ:INVA
1.1B USD 3.2 17.2 5.5 6.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 2.5 35.4 10.5 15.9
P/S Multiple
Revenue Growth P/S to Growth
US
Innoviva Inc
NASDAQ:INVA
Average P/S: 382 942.3
3.2
24%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
US
Innoviva Inc
NASDAQ:INVA
Average P/E: 30.6
17.2
-37%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Innoviva Inc
NASDAQ:INVA
Average EV/EBITDA: 414.1
5.5
11%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Innoviva Inc
NASDAQ:INVA
Average EV/EBIT: 1 810.8
6.9
38%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Discover More
Back to Top